Company Encyclopedia
View More
name
Phathom Pharmaceuticals
PHAT.US
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
4.599 T
PHAT.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking70/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE90.07%A
    • Profit Margin-186.53%E
    • Gross Margin87.50%A
  • Growth ScoreB
    • Revenue YoY460.30%A
    • Net Profit YoY19.12%B
    • Total Assets YoY-37.92%E
    • Net Assets YoY-125.82%E
  • Cash ScoreB
    • Cash Flow Margin-53.61%D
    • OCF YoY460.30%A
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreE
    • Gearing Ratio275.84%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CEO Basta Acquires 41,625 Of Phathom Pharmaceutials Inc [PHAT]

    Basta Steven L, CEO of Phathom Pharmaceuticals Inc [PHAT], filed a Form 4 with the SEC on December 2, 2025, disclosing changes in ownership. On November 28, 2025, he exercised 90,000 shares at $0.00 and surrendered 48,375 shares at $15.62, valued at $755,618, to cover option exercise costs and/or tax liabilities. His ending holdings are 83,250 shares directly.

    Reuters·
    US
    PHAT
    -0.07%
    Reuters·
    US
    PHAT
    -0.07%

    Govt imposes anti-dumping duty on Vietnam's hot rolled steel exports

    The Indian government has imposed an anti-dumping duty on hot rolled steel imports from Vietnam to protect domestic producers. This decision follows findings from the Directorate General of Trade Remedies, which indicated that Vietnamese exports were being sold below normal value, harming the local steel industry. The duty is set at $121.55 per metric tonne for most Vietnamese producers, while Hoa Phat Dung Quat Steel JSC is exempt. The duty will last for five years unless changed.

    Business Standard·
    US
    X
    0.00%
    US
    PHAT
    -0.07%
    Business Standard·
    US
    X
    0.00%
    US
    PHAT
    -0.07%

    Phathom Pharmaceuticals Principal Accounting Officer Robert Charles Breedlove Reports Sale of Common Shares

    Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals Inc., reported the sale of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. Phathom Pharmaceuticals published the original content via EDGAR on November 05, 2025.

    Reuters·
    US
    PHAT
    -0.07%
    Reuters·
    US
    PHAT
    -0.07%

    Phathom Pharmaceuticals Begins Phase 2 EoE Trial

    Phathom Pharmaceuticals (PHAT) has announced the start of its Phase 2 pHalcon EoE-201 clinical trial for VOQUEZNA® (vonoprazan) tablets, targeting eosinophilic esophagitis in adults. The trial will enroll 80 participants, with results expected in 2027. Analysts rate PHAT stock as a Buy with a $22.00 price target, though Spark's AI Analyst gives it a Neutral outlook due to financial instability and reliance on external financing. Phathom focuses on gastrointestinal disease treatments, with a current market cap of $976.7M.

    Tip Ranks·
    US
    PHAT
    -0.07%
    Tip Ranks·
    US
    PHAT
    -0.07%

    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

    FLORHAM PARK, N.J., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of its management team are scheduled ...

    GlobeNewswire·
    US
    PHAT
    -0.07%
    GlobeNewswire·
    US
    PHAT
    -0.07%
    © 2025 Longbridge｜Disclaimer